Your browser doesn't support javascript.
loading
Designing and Validating a Comprehensive Patient-Reported Outcomes Measure for Ambulatory Cancer Settings: The Revised Edmonton Symptom Assessment System for Cancer.
Watson, Linda; Link, Claire; Qi, Siwei; DeIure, Andrea; Chmielewski, Lindsi; Hildebrand, April; Barbera, Lisa.
Afiliación
  • Watson L; Applied Research & Patient Experience, Supportive Care Services and Patient Experience, Cancer Care Alberta, Alberta Health Services, Calgary, AB, Canada.
  • Link C; Faculty of Nursing, University of Calgary, Calgary, AB, Canada.
  • Qi S; Applied Research & Patient Experience, Supportive Care Services and Patient Experience, Cancer Care Alberta, Alberta Health Services, Calgary, AB, Canada.
  • DeIure A; Applied Research & Patient Experience, Supportive Care Services and Patient Experience, Cancer Care Alberta, Alberta Health Services, Calgary, AB, Canada.
  • Chmielewski L; Applied Research & Patient Experience, Supportive Care Services and Patient Experience, Cancer Care Alberta, Alberta Health Services, Calgary, AB, Canada.
  • Hildebrand A; Applied Research & Patient Experience, Supportive Care Services and Patient Experience, Cancer Care Alberta, Alberta Health Services, Calgary, AB, Canada.
  • Barbera L; Applied Research & Patient Experience, Supportive Care Services and Patient Experience, Cancer Care Alberta, Alberta Health Services, Calgary, AB, Canada.
JCO Oncol Pract ; : OP2400088, 2024 Jul 02.
Article en En | MEDLINE | ID: mdl-38954778
ABSTRACT

PURPOSE:

Patient-reported outcomes (PROs) information has been routinely collected in Cancer Care Alberta (CCA) for years using the revised Edmonton Symptom Assessment System (ESAS-r) and Canadian Problem Checklist (CPC). There was interest in combining these into a more comprehensive single measure tailored to ambulatory cancer settings. The purpose of this study was to validate an expanded and redesigned ESAS-r called the ESAS-r Cancer.

METHODS:

Stakeholder engagement, a review of the literature, and 2 years of CPC data collected in the cancer program informed the addition of six symptoms to the ESAS-r. To assess and validate the measure, 1,600 randomly sampled patients were mailed paper copies of the ESAS-r Cancer, ESAS-r, and a validated, comprehensive PRO measure called the Memorial System Assessment Scale-Short Form (MSAS-SF), which is often used with patients with cancer. Canonical Correlation Analysis and exploratory factor analyses were performed to assess concurrent and construct validity of the ESAS-r Cancer against ESAS-r, using MSAS-SF as the reference measure for comparison. Cronbach α was calculated to assess reliability.

RESULTS:

Four hundred and sixty-one patients (29% response rate) completed all three questionnaires. ESAS-r Cancer showed higher numerical correlation than ESAS-r and accounted for more information included on MSAS-SF, explaining slightly more variance than ESAS-r (75.2% v 73.5%). The three-dimensional factor structure of ESAS-r Cancer outperformed the two-dimensional factor structure of ESAS-r. The reliability of ESAS-r Cancer was verified and found to be slightly higher than ESAS-r (Cronbach α = .903 v .884).

CONCLUSION:

ESAS-r Cancer is now in use with patients throughout CCA. This valid and reliable PRO measure can be used by other cancer or specialized health care programs who wish to routinely assess common symptoms.

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: JCO Oncol Pract Año: 2024 Tipo del documento: Article País de afiliación: Canadá

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: JCO Oncol Pract Año: 2024 Tipo del documento: Article País de afiliación: Canadá
...